Health  For All

1 Reeve Crt

Cheltenham Vic 3192

Australia

Tel: +613 9584 9828

care@uct.com.au

HOME

More Information about Resperat

View Demonstration Now

Now with a money back guarantee!

Testimonials

More information

 

Interactive Breathing Device Found Effective
in Lowering High Systolic Blood Pressure

 gline.gif (856 bytes)

San Francisco, CA. - March 16, 2005 - Frost & Sullivan will present its 2005 Hypertension Treatment Technology Innovation of the Year Award to InterCure, Inc. for its pioneering Interactive Respiratory-Pacing technology, and in particular for its device RESPeRATE To Lower Blood Pressure� - the only FDA-cleared non-drug medical device clinically proven to lower high blood pressure. The Award will be presented at tonight's 2nd annual Excellence in Medical Devices Awards Banquet.

As over 60 million Americans suffer from hypertension and only approximately 30 percent of them successfully control their blood pressure, RESPeRATE� is expected to influence the treatment of hypertension extensively.

With multiple published clinical trials and thousands of advocates, both patients and physicians, RESPeRATE� is rapidly becoming a part of the standard of care for the treatment of hypertension. Besides being the only therapeutic self-care device treating a major cardiovascular condition, RESPeRATE� has become the first hypertension treatment available over-the-counter (OTC).

"This device uses a patented interactive respiratory-pacing technology to pace a patient's breathing from the normal rate of 14 to 19 breaths/minute, to the therapeutic zone of under 10 breaths/minute," explains Frost & Sullivan research analyst Miriam Nagel. "Within minutes, muscles surrounding the small blood vessels relax to allow the blood to flow more freely, reducing high blood pressure. When used 3 to 4 times a week for as little as 15 minutes at a time, RESPeRATE� was shown to reduce high blood pressure on a sustained basis by an average of 14/9 mmHg."

Nagel further explains that "This battery operated device, about the size of a paperback book, takes advantage of the body's natural tendency to follow external rhythms. The RESPeRATE� kit consists of a computerized control box, a respiration sensor, and headphones. By monitoring the patient's breathing rate and pattern, the device creates a personalized melody of two distinct tones - one tone for inhalation and one for exhalation," observes Nagel. "As patients listen to the melody and synchronize their breathing with these tones, the device gradually prolongs the exhalation tone, thereby pacing users to the slower therapeutic breathing zone."

In addition to RESPeRATE� To Lower Blood Pressure, InterCure has incorporated the technology platform in a second device, InTone�, a dyspnea-improving device for patients prone to mild-to-moderate heart failure. InTone has been tested successfully in Phase IIa clinical trials in which it has met or exceeded primary endpoints including significant improvements in QOL (quality of life), 6-minutes walk, ejection fraction, and pulmonary artery pressure. .

Frost & Sullivan presents its Technology Innovation of the Year Award to a company that has carried out new research that has resulted in innovations that have brought significant contributions to the industry in terms of adoption, change, and competitive posture. It recognizes the quality and depth of a company's research and development program, as well as the vision and risk-taking that enabled it to undertake such an endeavor in its industry.

Held in San Francisco, CA., Frost & Sullivan's 2005 Excellence in Medical Devices Awards Banquet honors world-class companies for outstanding performance and achievements in the medical devices industry.

About InterCure Inc.

InterCure (www.intercure.com) is a medical device company that creates and sells products that harness the therapeutic power of breathing for the treatment of hypertension, heart failure, respiratory diseases and other conditions. With 7 successful clinical trials, RESPeRATE� (www.resperate.com), InterCure's first product, became the only non-drug medical device indicated by the FDA for the adjunctive treatment of hypertension.

Contact:
Tom Kirwan
201.720.7750 x 7136
tkirwan@intercure.com

About Frost & Sullivan

Frost & Sullivan, a global growth consulting company founded in 1961, partners with clients to create value through innovative growth strategies. The foundation of this partnership approach is our Growth Partnership Services platform, whereby we provide industry research, marketing strategies, consulting and training to our clients to help grow their business. A key benefit that Frost & Sullivan brings to its clients is a global perspective on a broad range of industries, markets, technologies, econometrics, and demographics. With a client list that includes Global 1000 companies, emerging companies, as well as the investment community, Frost & Sullivan has evolved into one of the premier growth consulting companies in the world. For more information, visit www.frost.com.

Contact:
Stacie Jones
210.247.2450
Stacie.jones@frost.com